

# Surgical Antibiotic Prophylaxis - Pediatric

*This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.*

**Patients scheduled for surgery should have the following antibiotics administered prior to their procedure:**

- Vancomycin and ciprofloxacin are to be initiated 60 to 120 minutes prior to incision and all other antibiotics are to be initiated within 60 minutes of incision.
- Please carefully evaluate allergy histories before using alternative agents. The majority of patients with listed penicillin allergies can safely be given cephalosporins or carbapenems.
- If the patient has multiple known antibiotic drug allergies, is colonized with or has a history of a recent multi-drug resistant infection, please administer antibiotics as indicated or consider an Infectious Diseases consultation.
- Vancomycin prophylaxis 15 mg/kg IV (maximum 2,000 mg/dose) should be considered for patients with known MRSA colonization or at high risk for MRSA colonization in the absence of surveillance data (e.g., patients with recent hospitalization, hemodialysis patients).
- Discontinue all antibiotics within 24 hours of first dose except for: 1) Treatment of established infection, 2) Prophylaxis of prosthesis in the setting of postoperative co-located percutaneous drains, 3) Intraoperative findings that raise the wound classification above 2 (e.g., spillage of enteric contents, purulent fluid, etc.) All of these require appropriate documentation.
- See **Appendix A** for intraoperative re-dosing recommendations.
- Doses listed are based on actual body weight.

Disease Site	No Penicillin Allergy	Patients with Penicillin Allergy
Cardiac and Vascular Thoracic	Cefazolin 30 mg/kg IV (maximum 3,000 mg/dose)	<ul style="list-style-type: none"> <li>• Vancomycin 15 mg/kg IV (maximum 2,000 mg/dose) <b>or</b></li> <li>• Clindamycin 10 mg/kg IV (maximum 900 mg/dose)</li> </ul>
Head & Neck (ENT)	<ul style="list-style-type: none"> <li>• <b>Clean:</b> Cefazolin 30 mg/kg IV (maximum 3,000 mg/dose)</li> <li>• <b>Clean Contaminated:</b> Ampicillin/Sulbactam 50 mg/kg IV (maximum 2,000 mg/dose) (dose based on ampicillin component)</li> </ul>	Clindamycin 10 mg/kg IV (maximum 900 mg/dose)
Neurosurgery	Cefazolin 30 mg/kg IV (maximum 3,000 mg/dose)	Vancomycin 15 mg/kg IV (maximum 2,000 mg/dose)
Upper Gastrointestinal <sup>1</sup>	Cefazolin 30 mg/kg IV (maximum 3,000 mg/dose)	<ul style="list-style-type: none"> <li>• Vancomycin 15 mg/kg IV (maximum 2,000 mg/dose) <b>or</b></li> <li>• Clindamycin 10 mg/kg IV (maximum 900 mg/dose)</li> </ul>
Lower Gastrointestinal <sup>2</sup>	<ul style="list-style-type: none"> <li>• Cefoxitin 40 mg/kg IV (maximum 2,000 mg/dose) <b>or</b></li> <li>• Cefazolin 30 mg/kg IV (maximum 3,000 mg/dose) <b>plus</b></li> <li>• Metronidazole 15 mg/kg IV (maximum 500 mg/dose)</li> </ul>	<ul style="list-style-type: none"> <li>• Clindamycin 10 mg/kg IV (maximum 900 mg/dose) <b>plus</b></li> <li>• Gentamicin 2.5 mg/kg IV (maximum 80 mg/dose)</li> <li><b>or</b></li> <li>• Clindamycin 10 mg/kg IV (maximum 900 mg/dose) <b>plus</b></li> <li>• Ciprofloxacin 10 mg/kg IV (maximum 500 mg/dose)</li> </ul>
Orthopedics	<ul style="list-style-type: none"> <li>• <b>Pelvic Surgery:</b> Cefoxitin 40 mg/kg IV (maximum 2,000 mg/dose)</li> <li>• <b>Implanted Orthopedic Prosthesis:</b> Cefazolin 30 mg/kg IV (maximum 3,000 mg/dose) <b>plus</b> Gentamicin 2.5 mg/kg (maximum 80 mg/dose)</li> <li>• <b>All others:</b> Cefazolin 30 mg/kg IV (maximum 3,000 mg/dose)</li> </ul>	<ul style="list-style-type: none"> <li>• Vancomycin 15 mg/kg IV (maximum 2,000 mg/dose) <b>or</b></li> <li>• Clindamycin 10 mg/kg IV (maximum 900 mg/dose)</li> </ul>

<sup>1</sup> Upper gastrointestinal disease site is defined as esophagus through duodenum

<sup>2</sup> Lower gastrointestinal disease site is defined as jejunum through colon

*This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson’s specific patient population; MD Anderson’s services and structure; and MD Anderson’s clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.*

## APPENDIX A: Recommended IntraOp Redosing Intervals for Commonly Used Antimicrobials for Surgical Prophylaxis for Patients with Normal Renal Function<sup>1</sup>

Antimicrobial	Recommended Redosing Interval (From initiation of Preoperative Dose), hr <sup>2</sup>
Ampicillin-sulbactam	2
Cefazolin	4
Cefoxitin	2
Ciprofloxacin <sup>3</sup>	N/A
Clindamycin	6
Gentamicin <sup>4</sup>	N/A
Metronidazole	N/A
Vancomycin <sup>5</sup>	N/A

<sup>1</sup> Patients with impaired renal function need individualized initial and secondary antibiotic dosing based on glomerular filtration rate (GFR) and case type.

<sup>2</sup> For antimicrobials with a short half-life (*e.g.*, ampicillin-sulbactam, cefoxitin) used before long procedures, redosing in the operating room is recommended at an interval of approximately two times the half-life of the agent in patients with normal renal function and is at the discretion of the surgeon based on the clinical scenario. Recommended redosing intervals marked as “not applicable” (NA) are based on typical case length; for unusually long procedures, redosing may be needed.

<sup>3</sup> While fluoroquinolones have been associated with an increased risk of tendinitis/tendon rupture in all ages, use of these agents for single-dose prophylaxis is generally safe.

<sup>4</sup> In general, gentamicin for surgical antibiotic prophylaxis should be limited to a single dose given preoperatively. Dosing is based on the patient’s actual body weight.

<sup>5</sup> Vancomycin prophylaxis should be considered for patients with known MRSA colonization or at high risk for MRSA colonization in the absence of surveillance data (*e.g.*, patients with recent hospitalization, hemodialysis patients).

*This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.*

---

## SUGGESTED READINGS

- American Society of Health-System Pharmacists. (2013). ASHP therapeutic guidelines on clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm.* 70:600-686.
- Kimberlin, D. W., Brady, M. T., Jackson, M. A., & Long, S. S. (2015). Antimicrobial prophylaxis in pediatric surgical patients. Red Book: 2015 Report of the Committee on Infectious Diseases. 30<sup>th</sup> ed. Elk Grove Village, IL: *American Academy of Pediatrics*; 824.

*This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.*

---

## DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Faculty at the University of Texas, MD Anderson Cancer Center. A multidisciplinary approach was used and included input from the following surgical oncologists and infectious disease specialists:

Samuel Aitken, PharmD  
Natalie J.M. Dailey Garnes, MD  
Yoliette Goodman, MBA<sup>♦</sup>  
Andrea Hayes-Jordan, MD<sup>‡</sup>  
Valerae Lewis, MD  
Sonal P. Yang, PharmD, BCPS<sup>♦</sup>

<sup>‡</sup> Physician Leads

<sup>♦</sup> Clinical Effectiveness Development Team